## At a glance

Results for the FY2022

**EBITDA** 

14.5

2018

15.4

2019

2020

**REPORT 2023** 


CHOUZAI INTEGRATED


NOHIN

21

a glance

At





16.3 billion yen

14.9

2021

16.3

2022 (FY)





Promoting generic drug use by harnessing strong synergies with the Pharmaceutical Manufacturing and Sales Business \*discontinued products have been excluded from calculations


80,000<sub>cases</sub> Providing high-value-added services

with superlative matching quality

1,400,000 As of March 2023

> Enhancing convenience and supporting patient health

\* Ranked #1 in the number of members of in-house developed applications for pharmacy chains and drugstores.



Ongoing strategy of opening pharmacies with an emphasis on balance between hospitalfront/on-site pharmacies and hybrid pharmacies

As of March 2023

## Support for Advanced Medical Care

Proportion of Nihon Chouzai pharmacists certified in outpatient oncology by JASPO\*

28%

Placement of highly specialized pharmacists such as those accredited by an academic society \*Japanese Society of Pharmaceutical Oncology

Prescription unit price



Track record of handling highly specialized drugs